Algaia discloses the name of its new strategic investor
PARIS, France — September 26nd, 2016: Algaia SA, following its declaration of intent last week to acquire Cargill’s Alginate business, announces the name of its new investor. Upon closing, Algaia will welcome Maabarot Products Ltd. in its shareholding structure. ...
Algaia announces its intent to acquire Cargill’s Alginate business and its French manufacturing facility of Lannilis
PARIS, France — September 16st 2016: Algaia (previously named Eviagenics) strengthens its presence in the field of natural seaweed extracts and makes a significant step forward in its development. It has entered today into a handshake agreement with Cargill to...
ALGAIA opens a new R&D center in Saint-Lô in September
By end of 2016, ALGAIA will open a new R&D centre in Saint-Lô (Normandy, France), strategically located next to numerous development centres and ...
EVIAGENICS acquires ALGANACT and becomes ALGAIA
VILLEJUIF, France – June 1st 2016: Eviagenics continues its metamorphosis with the acquisition of assets, know-how and team of Alganact SA, a French start-up company specialized in the development, characterization and production of specialty seaweed...
EVIAGENICS strengthens its management team
EVIAGENICS strengthens its management team and continues its metamorphosis Link to the Official Press Release Link to the “Formule verte” article
EVIAGENICS sells its flavonoid Biotech platform to Alderys
EVIAGENICS concluded the sale of its Flavonoid Biotech platform to Alderys, a well-established French Biotech firm located at Orsay Link to the Official Press Release Link to the “Formule verte” article Link to the “Nutra-ingredients”...
EVIAGENICS sells its Vanillin technology
EVIAGENICS concluded in June 2015 the sale of its yeast based Vanillin technology (and related patents) to a large industrial player. The terms and conditions of this transaction are confidential. Algaia is now concentrating its Biotech R&D efforts to specific...
EVIAGENICS raises 2.5m€ additional funding for its strategy
EVIAGENICS raises 2.5m€ additional funding from its current investors to deploy its strategy related to seaweed extracts .